Metraipolis › archive › dc_02656330e6fd

Pyrazolone-based ERO1 inhibitors in ERO1-driven triple-negative breast cancer and SEPN1-related myopathy: Structure-activity relationship and therapeutic… — Europe PMC PMID:41270850

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41270850
DOI
10.1016/j.phrs.2025.108037
License (as archived)
solo-consultazione
Archived
2026-11-08T10:45:55.603Z
SHA-256 of the archived text
39bb312783f822d2bfc95721f7b67bb0b70d14353496880dca0fe43a607051cd
Stable URL of this page
https://metraipolis.com/documento/dc_02656330e6fd

How to cite

Pyrazolone-based ERO1 inhibitors in ERO1-driven triple-negative breast cancer and SEPN1-related myopathy: Structure-activity relationship and therapeutic… — Europe PMC PMID:41270850 — Europe PMC (en), https://europepmc.org/article/MED/41270850 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_02656330e6fd (Metraipolis archive dc_02656330e6fd, sha256 39bb312783f822d2bfc95721f7b67bb0b70d14353496880dca0fe43a607051cd)
BibTeX
@misc{dc02656330e6fd,
  title = {Pyrazolone-based ERO1 inhibitors in ERO1-driven triple-negative breast cancer and SEPN1-related myopathy: Structure-activity relationship and therapeutic… — Europe PMC PMID:41270850},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41270850},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_02656330e6fd; sha256 39bb312783f822d2bfc95721f7b67bb0b70d14353496880dca0fe43a607051cd},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41270850. Agents can read the archived copy with the MCP tool read_document.